文献速递炎症性肠病

托法替布剂量升降在溃疡性结肠炎中的疗效与安全性:OCTAVE Open 结果

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-29

OCTAVE Open 开放标签长期扩展研究评估托法替布剂量降阶与升阶在溃疡性结肠炎患者中的疗效与安全性。降阶组 66 例经 10 mg 每日两次维持缓解后降至 5 mg 每日两次,升阶组 57 例 5 mg 每日两次治疗失败后升至 10 mg 每日两次。降阶后第 12 个月 74.6% 维持缓解;升阶后第 12 个月 49.1% 达到缓解,升阶组带状疱疹发生率数值上高于整体项目。

要点

  • 10 mg 每日两次维持缓解后降阶至 5 mg 每日两次,第 12 个月 74.6% 维持缓解。
  • 5 mg 每日两次治疗失败后升阶至 10 mg 每日两次,第 12 个月 49.1% 达到缓解。
  • 升阶组带状疱疹发生率数值上高于整体托法替布 UC 项目。

核心结论

  • 已在 10 mg 每日两次维持缓解的患者降阶后多数维持缓解,但第 12 个月有 25.4% 失去缓解。
  • 5 mg 每日两次维持治疗失败的诱导应答者升阶至 10 mg 每日两次后,第 12 个月 49.1% 达到缓解。

研究设计与样本

  • 降阶组 66 例为托法替布诱导应答者,经 52 周 10 mg 每日两次维持治疗缓解后降阶至 5 mg 每日两次。
  • 升阶组 57 例为托法替布诱导应答者,在 5 mg 每日两次维持治疗期间治疗失败后升阶至 10 mg 每日两次。

主要发现

  • 降阶后第 2 个月和第 12 个月分别有 92.4%(61/66)和 84.1%(53/63)维持临床应答。
  • 降阶后第 2 个月和第 12 个月分别有 80.3%(53/66)和 74.6%(47/63)维持缓解。
  • 升阶后第 2 个月和第 12 个月分别有 57.9%(33/57)和 64.9%(37/57)重新获得临床应答。
  • 升阶后第 2 个月和第 12 个月分别有 35.1%(20/57)和 49.1%(28/57)达到缓解。
  • 升阶组带状疱疹发生率为 7.6 例事件/100 患者年,数值上高于整体托法替布 UC 项目。

临床怎么用

  • 对 10 mg 每日两次维持缓解的 UC 患者可考虑降阶至 5 mg 每日两次,但需监测约四分之一患者第 12 个月失去缓解。
  • 对 5 mg 每日两次维持治疗失败的诱导应答者可升阶至 10 mg 每日两次,第 12 个月约半数达到缓解。
  • 升阶至 10 mg 每日两次时需关注带状疱疹风险,发生率数值上高于整体项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. AIM: To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients with UC. METHODS: We evaluated data (November 2017 data cut-off) from OCTAVE Open, an ongoing, open-label, long-term extension study. The dose de-escalation group comprised 66 tofacitinib induction responders in remission following 52 weeks' tofacitinib 10 mg b.d. maintenance therapy, subsequently de-escalated to 5 mg b.d. in OCTAVE Open. The dose escalation group comprised 57 tofacitinib induction responders who experienced treatment failure while receiving 5 mg b.d. maintenance therapy, subsequently escalated to 10 mg b.d. in OCTAVE Open. RESULTS: After tofacitinib de-escalation, 92.4% (61/66) and 84.1% (53/63) of patients maintained clinical response and 80.3% (53/66) and 74.6% (47/63) maintained remission, at months 2 and 12, respectively. After dose escalation, 57.9% (33/57) and 64.9% (37/57) of patients recaptured clinical response and 35.1% (20/57) and 49.1% (28/57) were in remission, at months 2 and 12, respectively. The incidence rate of herpes zoster with dose escalation (7.6 patients with events/100 patient-years) was numerically higher than in the overall tofacitinib UC programme. CONCLUSIONS: Following tofacitinib de-escalation in patients already in remission on 10 mg b.d., most maintained remission, although 25.4% lost remission, at month 12. For induction responders who dose-escalated following treatment failure on 5 mg b.d. maintenance therapy, 49.1% achieved remission by month 12. (ClinicalTrials.gov number: NCT01470612).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2019. PMID: 31660640. doi:10.1111/apt.15555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。